Characteristics of international drug regulatory regimes

August 14, 2017, University of Basel

The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. This reports a study of the European Center of Pharmaceutical Medicine at the University of Basel. The results were published in the journal Nature Reviews Drug Discovery.

The researchers compared the regulatory authorities responsible for approving drugs and medical products in 12 countries, among them, for example, Swissmedic in Switzerland and the U.S. Food and Drug Administration (FDA). The results show that international encounter very different regional requirements.

Depending on the country, identical products are being evaluated not only according to different standards and processes to verify their effectiveness and safety, but certain aspects are also being reviewed and assessed multiple times and in various ways.

Harmonization could increase efficiency

The regulatory hurdles for approval (fees, studies, evaluation periods, etc.) are known to be a significant time factor in the global development. Different approval requirements prolong the time until the market entry of new, innovative drugs which also impacts their price. The study thus shows that a harmonization of these approval requirements and processes could significantly improve efficiency.

"Patients would profit especially since would be available faster and at lower prices," comments Prof. Dr. Thomas D. Szucs from the European Center of Pharmaceutical Medicine at the University of Basel. "This suggests that companies and authorities should strengthen their international collaboration and communicate better with each other."

With their study, the researchers hope to contribute to higher cost efficiency in the development of drugs and shorter authorization processes.

Explore further: Drug access delays due to pharmaceutical companies not Health Canada

More information: Anand B. Jain et al. Regulatory watch: Structural and procedural characteristics of international regulatory authorities, Nature Reviews Drug Discovery (2017). DOI: 10.1038/nrd.2017.135

Related Stories

Drug access delays due to pharmaceutical companies not Health Canada

May 12, 2014
Access to new prescription drugs in Canada is delayed by pharmaceutical company submissions to Health Canada rather than by a longer approval-processing time, according to an analysis published in CMAJ (Canadian Medical Association ...

Drug research and development more efficient than expected

February 27, 2015
Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

FDA addresses concerns on approval of drugs to treat chronic hepatitis C

June 2, 2015
Treatment options for chronic hepatitis C, a serious and life-threatening infection, have improved substantially and several new regimens with shorter durations and improved efficacy and safety profiles are now available.

FDA approves drugs more quickly than peer agency in Europe: study

April 5, 2017
The U.S. Food and Drug Administration (FDA) reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency (EMA), says a Yale researcher. This finding, which comes ...

Recommended for you

Health insurer policies may discourage use of non-opioid alternatives for lower back pain

October 5, 2018
Public and private health insurance policies in the U.S. are missing important opportunities to encourage the use of physical therapy, psychological counseling and other non-drug alternatives to opioid medication for treating ...

Opioid overdoses, depression linked

October 3, 2018
The link between mental health disorders and substance abuse is well-documented. Nearly one in 12 adults in the U.S is depressed, and opioid-related deaths are skyrocketing. As these numbers continue to climb, some mental ...

Do price spikes on some generic drugs indicate problems in the market?

October 1, 2018
A new USC study reports that sudden price spikes for some generic drugs—such as the recently reported increases of a decades-old generic heart medication and an antibiotic—are becoming more common.

Reclassification recommendations for drug in 'magic mushrooms'

September 26, 2018
In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, Johns Hopkins researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule ...

New study finds concurrent use of prescription drugs and dietary supplements could pose health risks

September 25, 2018
A new University of Hertfordshire study found that using certain over-the-counter herbal medicines and dietary supplements alongside prescription drugs could pose serious health risks, especially amongst older adults.

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.